Cilia appear in a wide variety of cell types, including osteoclasts and osteoblasts, where they function as physiologic and biochemical sensors.
Cilia appear in a wide variety of cell types, including osteoclasts and osteoblasts, where they function as physiologic and biochemical sensors.
Christopher Jacobs, PhD, from Columbia University, discussed the interplay between mechanobiology and biomechanics in primary cilia at the 2014 American Society of Bone and Mineral Research Conference in Houston, Texas.
Individual cells and cell types encounter the outside world differently. Osteoclasts and osteoblasts react to outside forces imposed on them by activities such as strain, exercise, and sitting. Endothelial cells respond to the mechanical stress caused by laminar blood flow, and cellular mechanical transduction is at the center of atherosclerosis.
Primary cilia are single antenna-like structures emerging from each cell. As Dr Jacobs said, “they are not vestigial, not the appendix of the cell.” They specifically function as physiologic and biochemical sensors in cells as diverse as cholangiocytes, osteocytes, and chondrocytes.
In bone, primary cilia function in bone transduction and the lack of cilia interferes with PGE2 release in osteoblasts.
In his talk, Dr Jacobs said that biomechanical changes in the environment alter how the cell can use the cilium as a biochemical sensor. Primary cilia deflect with flow. As a cilium experiences variable timing and force of the flowing air or liquid to which it is exposed, it may change its organization and remodel as it bends.
The microtubular network anchoring the base of cilium becomes enhanced, and this sub-cellular structure seems to be a sensor that adapts to its environment. Primary cilia stiffness can be modulated, as can torsional stiffness. Increased stiffness correlates with the degree of biomechanical sensitivity.
According to Dr Jacobs, future directions for the study of cilia include answering questions about the nature of calcium and other biochemical channels in cilia compared with other cell types. He is also exploring the role of cilia in mesenchymal stem cells.
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
“Expanding Access Isn’t Just About Fairness—It’s About Building Better Treatments for Everyone”
February 16th 2025Regina Barragan-Carrillo, MD, a postdoctoral fellow at City of Hope Comprehensive Cancer Center, discussed findings that show 76% of renal cell carcinoma trials take place in wealthy countries, amid news that clinical trial access for the world's poor may become even more challenging.
Read More
Amid Debate Over Diversity, RCC Trials Still Struggle to Reflect Patient Populations
February 16th 2025Abstracts presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium reflect the ongoing challenge with enrolling diverse patient populations in trials, despite stated goals.
Read More